Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.67 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041756 | 0.81 | MYLK4 (0.62) | BRAF | |
| SCHEMBL3034030 | 0.75 | BRAF (0.68) | BRAFRAF1 | |
| SCHEMBL25881484 | 0.73 | MYLK4 (0.48) | BRAF | |
| SCHEMBL5132890 | 0.73 | BRAF (0.61) | BRAFRAF1 | |
| SCHEMBL12639583 | 0.73 | AURKA (0.57) | CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17047495 | 0.72 | BRAF (0.63) | BRAFRAF1 | |
| SCHEMBL5129995 | 0.72 | BRAF (0.77) | BRAFRAF1 | |
| SCHEMBL12305275 | 0.71 | AURKA (0.64) | CYP3A4CYP2C19 | |
| SCHEMBL5133168 | 0.71 | BRAF (0.84) | BRAFRAF1 | |
| SCHEMBL3042216 | 0.71 | BRAF (0.68) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885CYP3A4 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.